GUIDEPOINT INSIGHTS AASLD VIRTUAL GROUP MEETINGS
On Sunday, November 15th, and Monday, November 16th, Guidepoint Insights will be hosting a series of 45-minute virtual group meetings featuring KOLs who will dive deeper into the American Association for the Study of Liver Diseases (AASLD) data updates.
Topics of discussion will include:
- Review of incremental data for NAFLD/NASH studies including REGENERATE(obeticholic acid), FLIGHT-FXR (tropifexor), MAESTRO-NAFLD-1 (resmetirom), FASCINATE-1 (TVB-2640), NATIVE (lanifibranor), BALANCED (efruxifermin), ATLAS (firsocostat/cilofexor), aldafermin, seladelpar, BIO89-100, AXA1125, AXA1957 among others
- Thoughts on the long-term efficacy of obeticholic acid in PBC and potential opportunity for saroglitazar and linerixibat. Takeaways from INTREPID Study evaluating EDP-305 in PBC and potential read-through for ongoing ARGON-2 NASH trial
- Discussion of therapeutic updates in hepatitis including vebicorvir, JNJ-0440, JNJ-3989, AB-729, RG6346, GSK3228836, ALG-000184, ISIS 505358, and others
- Abstract review for rare cholestatic diseases: odevixibat and maralixibat
Complete the form below to request access:
AASLD meetings will not be recorded and transcripts will not be available after the event. To recreate conditions similar to an in-person meeting, this event will be conducted as a Zoom meeting. As such, participants will be able to see/identify each other.